Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

University of Chinese Academy Sciences

Status and phase: Completed; Phase 2

Conditions: Nasopharyngeal Carcinoma

Treatments: Radiation: Radiation; Drug: Nimotuzumab

Study type: Interventional

Funder types: Other

Identifiers

NCT03025958

ZJCH-2016-HN04

Details and patient eligibility

About

Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Full description

Elderly patients with locoregionally advanced nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent radiotherapy, weekly nimotuzumab (200 mg/week).

Enrollment: 30 patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previously untreated and histologically confirmed locoregionally advanced nasopharyngeal carcinoma

Exclusion criteria

• A history of another invasive cancer, prior RT to the head and neck area, prior cytotoxic chemotherapy or anti-EGFR therapy or the presence of any serious medical conditions, supposed to live less than 6 months.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Nimotuzumab

Experimental group

Description:

Elderly patients with locoregionally advanced nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent radiotherapy, weekly nimotuzumab (200 mg/week).

Treatment:

Radiation: Radiation

Drug: Nimotuzumab